Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by Stanley Muller on Jul 24th, 2026

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-three ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, nineteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $261.4762.

A number of research analysts have recently weighed in on AXSM shares. BMO Capital Markets assumed coverage on Axsome Therapeutics in a report on Monday. They issued an “outperform” rating and a $310.00 target price on the stock. Wells Fargo & Company upped their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Robert W. Baird increased their price target on Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. UBS Group raised their price objective on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $290.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, July 15th.

Read Our Latest Report on AXSM

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $241.53 on Friday. Axsome Therapeutics has a twelve month low of $96.09 and a twelve month high of $260.19. The stock’s 50 day moving average is $238.98 and its 200-day moving average is $200.32. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. The firm has a market capitalization of $12.43 billion, a price-to-earnings ratio of -64.75 and a beta of 0.60.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The firm’s revenue for the quarter was up 57.4% on a year-over-year basis. Sell-side analysts forecast that Axsome Therapeutics will post -2.45 EPS for the current fiscal year.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 4,517 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $227.94, for a total value of $1,029,604.98. Following the completion of the sale, the chief operating officer owned 4,517 shares in the company, valued at approximately $1,029,604.98. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Nick Pizzie sold 33,000 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at approximately $10,291,938.03. This represents a 43.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 155,852 shares of company stock valued at $37,230,112 over the last three months. Insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp grew its stake in Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after purchasing an additional 7,320 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after purchasing an additional 84,151 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Axsome Therapeutics during the 1st quarter valued at $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after purchasing an additional 17,250 shares during the period. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.